abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb
Article

3 Mar 2009

Author:
Rajat Khosla & Paul Hunt, Human Rights Centre, University of Essex

[PDF] Human rights guidelines for pharmaceutical companies in relation to access to medicines: The sexual and reproductive health context

The application of human rights may vary from one type of actor to another…[T]he logic of human rights will inevitably lead to their application, in one form or another, to non-State actors…This briefing examines the issue of access to medicines in the context of sexual and reproductive health…[It] considers the responsibilities of pharmaceutical companies for enhancing access to medicines…[T]he Guidelines are grouped by themes, such as transparency, management, monitoring and accountability, pricing and ethical marketing. Each theme is followed by a brief Commentary…The Guidelines are based on human rights principles that are enshrined in the Universal Declaration of Human Rights. [refers to Abbott Laboratories, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, F. Hoffmann-La Roche, Novartis, NovoNordisk, Merck & Co.]